Sage Therapeutics, Inc. (NASDAQ:SAGE) reached 200.23% versus a 1-year low price of $26.55. The stock was last seen 3.32% higher, reaching at $79.71 on Jun. 16, 2017. At recent session, the prices were hovering between $76.06 and $80.3. This company shares are 6.82% off its target price of $85.15 and the current market capitalization stands at $2.88B. The recent change has given its price a 13.26% lead over SMA 50 and -0.33% deficit over its 52-week high. The stock witnessed 21.9% gains, 18.39% gains and 66.24% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SAGE’s volatility during a week at 5.27% and during a month it has been found around 4.6%.Sage Therapeutics, Inc. (SAGE) Top Holders
Institutional investors currently hold around $3.07 billion or 94% in SAGE stock. Look at its top three institutional owners. Fmr Llc owns $445.62 million in Sage Therapeutics, Inc., which represents roughly 15.47% of the company’s market cap and approximately 14.53% of the institutional ownership. Similar statistics are true for the second largest owner, Price T Rowe Associates Inc /Md/, which owns 3,333,190 shares of the stock are valued at $265.69 million. The third largest holder is Blackrock Inc., which currently holds $228.22 million worth of this stock and that ownership represents nearly 7.92% of its market capitalization.Sage Therapeutics, Inc. 13F Filings
At the end of Mar reporting period, 99 institutional holders increased their position in Sage Therapeutics, Inc. (NASDAQ:SAGE) by some 5,426,661 shares, 86 decreased positions by 5,761,223 and 20 held positions by 27,272,030. That puts total institutional holdings at 38,459,914 shares, according to SEC filings. The stock grabbed 46 new institutional investments totaling 1,670,805 shares while 15 institutional investors sold out their entire positions totaling 758,444 shares.Sage Therapeutics, Inc. (NASDAQ:SAGE) Insider Trades
Multiple company employees have indulged in significant insider trading. Sage Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CFO, Secretary and Treasurer IGUCHI KIMI has sold 10,000 shares of Sage Therapeutics, Inc. (SAGE) in trading session dated Jan. 13, 2017. These shares are worth $539,200 and were traded at $53.92 each. The SEC filing shows that IGUCHI KIMI performed a sale of 4,000 shares. The CFO, Secretary and Treasurer disposed these shares by way of transaction on Nov. 17, 2016. The company’s shares were given away at $51.77 per share worth to an income of some $207,080 on account of IGUCHI KIMI.
, Anderson Thomas, sold 10,000 common shares of Sage Therapeutics, Inc. (SAGE) in the open market. In a transaction dated Nov. 15, 2016, the shares were put up for sale at an average price of $55, raking in a sum of $550,000.
In the transaction dated Nov. 11, 2016, the great number of shares disposed came courtesy the CFO, Secretary and Treasurer; IGUCHI KIMI disposed a total of 1,500 shares at an average price of $50.59, amounting to approximately $75,885. The insider now directly owns 79,739 shares worth $6,355,996.Sage Therapeutics, Inc. (SAGE) Analyst Guide
Several analysts have released their opinion on Sage Therapeutics, Inc. (NASDAQ:SAGE), with 8 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.45 average brokerage recommendation.